# PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer

> **NCT04518800** · NA · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- PEG-rhG-CSF
- Pancreatic Cancer

## Interventions

- **DRUG:** Jin Youli(PEG-rhG-CSF)

## Key facts

- **NCT ID:** NCT04518800
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-18
- **Primary completion:** 2021-08-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518800, "PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04518800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*